ECE2023 Poster Presentations Diabetes, Obesity, Metabolism and Nutrition (159 abstracts)
En route to sarcopenia biomarkers: dp-ucMGP in relation to muscle mass and function
Veronika Tandl 1 , Natascha Schweighofer 1 , Olivia Trummer 1 , Christoph W. Haudum 1 , Alice F. Lind 1 , Ewald Kolesnik 2 , Ines Mursic 1 , Daniel Scherr 2 , Andreas Zirlik 2 , Thomas R. Pieber 1 , Nicolas D. Verheyen 2 & Barbara Obermayer-Pietsch 1
1Medical University of Graz, Department of Internal Medicine, Division of Endrocrinology and Diabetology, Graz, Austria; 2Medical University of Graz, Department of Internal Medicine, Division of Cardiology, Graz, Austria
Sarcopenia is characterized by progressive loss of both mass and function of skeletal muscle when ageing. It poses a serious issue for healthcare systems, as it is associated with increased risk of falls, osteoporosis, and mortality. To date, no ideal serum biomarkers for the diagnosis of this complex condition have been identified. Matrix-GLA-protein (MGP), primarily known as a vitamin K dependent calcification inhibitor, is present and active in bone, muscle, and adipose tissue. It acts as an adipokine and has been linked to reduced muscle strength. Therefore, its dephosphorylated and uncarboxylated isoform (dp-ucMGP) was investigated as a potential biomarker in sarcopenia. To find associations of dp-ucMGP and sarcopenia related parameters, data from the BioPersMed cohort (“Biomarkers for Personalized Medicine”) were analyzed. The cohort included 1022 asymptomatic volunteers (58±9 years) at moderate cardiovascular risk. In 760 persons, serum measurements of dp-ucMGP were analyzed with the InaKtif MGP Kit using the IDS-iSYS Multi-Discipline Automated System. Body composition was measured by Lunar iDXA and clinical and physical performance data were collected. Several sarcopenia definitions were used, based on either muscle mass (appendicular muscle mass [ASM] or appendicular muscle mass index [AMMI]) or muscle function (handgrip strength [HGS] or 400m walk test). Dp-ucMGP plasma levels correlated negatively with gait speed (Spearman’s rho [ρ]= 0.192; P<0.001). Using gait speed for defining groups, serum levels were higher in the sarcopenia compared to the non-sarcopenia group (716±306.6 vs. 491 ± 164.4 pmol/l; P= 0.006). The highest dp-ucMGP quartile also showed the highest risk of reduced HGS, another marker of physical performance (Odds ratio [OR] = 3.688; 95% CI 1.007 - 13.502). Other than with muscle function, dp-ucMGP showed a positive correlation to the muscle mass parameters AMS (ρ= 1.102; P= 0.005) and AMMI (ρ= 0.122; P= 0.001). Serum levels were lower in persons with sarcopenia than without, using both ASM and AMMI for defining groups (P<0.001 and P= 0.012, respectively). The lowest dp-ucMGP quartile had the highest risk for reduced muscle mass (i.e., AMMI), decreasing with each quartile. In sum, dp-ucMGP plasma levels are lower in sarcopenia defined by muscle mass (i.e., ASM and AMMI), but higher in sarcopenia defined by muscle function (i.e., HGS and gait speed). Serum dp-ucMGP can be considered as a potential biomarker candidate for characterizing sarcopenia and may be a promising link between bone, fat, and muscle.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more